The short version of Alpha-MSH fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-31 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
6 CO2 + 6 H2O → C6H12O6 + 6 O2 For example, large blooms of plankton (free-floating organisms) absorb large amounts of 12C from the oceans. Originally, the 12C was mostly incorporated into the seawater from the atmosphere. If the oceans that the plankton live in are stratified (meaning that there are layers of warm water near the top, and colder water deeper down), then the surface water does not mix very much with the deeper waters, so that when the plankton dies, it sinks and takes away 12C from the surface, leaving the surface layers relatively rich in 13C. Where cold waters well up from the depths (such as in the North Atlantic), the water carries 12C back up with it; when the ocean was less stratified than today, there was much more 12C in the skeletons of surface-dwelling species. Other indicators of past climate include the presence of tropical species and coral growth rings.
=== Off-label drugs === Acetazolamide (Diamox) – carbonic anhydrase inhibitor Atomoxetine (Strattera) – norepinephrine reuptake inhibitor (NRI) Eszopiclone (Lunesta) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/Z-drug Oxybutynin (Ditropan) – muscarinic acetylcholine receptor antagonist (anticholinergic) Pimavanserin (Nuplaizid) – serotonin 5-HT2A receptor antagonist Sodium oxybate (GHB; Xyrem) – GABAB receptor agonist and GHB receptor agonist Trazodone (Desyrel) – various actions Weight-loss drugs (e.g., liraglutide, semaglutide) – obesity-related sleep apnea
=== 2010-2013 === In 2010, Janusz Bugajski argued that Vladimir Putin and Dmitry Medvedev "were convinced that Europe and the United States needed Russia much more than Russia needed the West and calculated that several tangible advantages would be gained from the military attack on Georgia". In 2011, Michael Cecire explained that "citations of ’US training’ to Georgian troops have limited relevance in the context of the August war" since Americans trained Georgians for fighting with the insurgents and not for the war with Russia. Cecire further states: "The absence of Georgia's best troops has also been cited as being one of the clearest signs that Tbilisi did not have a premeditated intention to get into a war, and certainly not one with the Russian military. [...] Many observers agree that even if Georgia did premeditate the August 2008 war (and that is a big if), it was not counting on Russian involvement". In 2011, Dr. Ariel Cohen and Colonel Robert E. Hamilton wrote, "The Vladimir Putin-Dmitry Medvedev administration and the defense establishment formulated far-reaching goals when they carefully prepared over 2 1/2 years for a combined operations-style invasion of Georgia.
Sources: en.wikipedia.org
Overpayments can either be the fault of Social Security or of the recipient, for example, a person on SSDI disability not reporting monthly work income over a certain threshold. The Biden administration had capped the clawback rate at 10%, but this expired on March 27, 2025, reverting to 100%. On April 25, the Trump administration reduced this clawback rate to 50%.
There were concerns in the 2000s about the sugar and vitamin content of Ribena, a blackcurrant-based syrup and soft drink owned by GSK until 2013. Produced in England by H.W. Carter & Co from the 1930s, the company's unbranded syrup was distributed to children as a source of vitamin C during World War II, which gave the drink a reputation as good for health. Beecham bought H. W. Carter in 1955. In 2001, the British Advertising Standards Authority (ASA) required GSK to withdraw its claim that Ribena Toothkind, a lower-sugar variety, did not encourage tooth decay. A company poster showed bottles of Toothkind in place of the bristles on a toothbrush. The ASA's ruling was upheld by the High Court. In 2007, GSK was fined US$217,000 in New Zealand over its claim that ready-to-drink Ribena contained high levels of vitamin C, after two schoolgirls showed it contained no detectable vitamin C. In 2013, GSK sold Ribena and another drink, Lucozade, to the Japanese multinational Suntory for £1.35 billion.
=== Neutron scattering === Perdeuteration of one component of a multi-component system can provide contrast for neutron scattering experiments, where the contrast obtained by using deuterated solvents is insufficient.
Sources: en.wikipedia.org
History of chemical physics – history of the branch of physics that studies chemical processes from the point of view of physics and engineering. History of oenology – history of the science and study of all aspects of wine and winemaking except vine-growing and grape-harvesting, which is a subfield called viticulture. History of spectroscopy – history of the study of the interaction between matter and radiated energy History of surface science – history of the study of physical and chemical phenomena that occur at the interface of two phases, including solid–liquid interfaces, solid–gas interfaces, solid–vacuum interfaces, and liquid–gas interfaces. History of chemicals History of chemical elements - The concept of an "element" as an indivisible substance has developed through three major historical phases: Classical definitions (such as those of the ancient Greeks), chemical definitions, and atomic definitions. History of carbon History of hydrogen Timeline of hydrogen technologies History of oxygen History of chemical products History of aspirin History of cosmetics History of gunpowder History of pharmaceutical drugs History of vitamins History of chemical processes History of manufactured gas History of the Haber process History of the chemical industry History of the petroleum industry History of the pharmaceutical industry History of the periodic table
Specialized scalp tattoos can also mimic the appearance of a short buzzed haircut. Androgenic alopecia also occurs in women, and more often presents as diffuse thinning without hairline recession. Like its male counterpart, the condition rarely leads to total hair loss. Treatment options are similar to those for men, although topical or systemic estrogen is used more often.
A World Health Organization (WHO) Probe should be used. Refer to attached picture for WHO Probe. The World Health Organization (WHO) Probe has a ball ended tip which is 0.5mm in diameter and some have 2 black bands for dental professionals to measure periodontal pocket depth. A light force equivalent to the weight of the probe should be used. World Health Organization (WHO) Probe ranges in mass from 20 to 25 grams. The probe should be run around the gingival pockets and the highest score derived in each sextant derived should be recorded. Scoring codes range from 0 to 4. This can be accessed based on the flow table attached. A “*” is recorded when a furcation is involved. For patients with BPE scores of codes 3 and 4, more detailed charting is required. The presence of code 3 would indicate that a 6-point pocket charting in the sextant(s) where code 3 was recorded is required. If code 4 is recorded, a 6-point pocket charting throughout the entire dentition would be required. Usually, radiographs would be taken to evaluate alveolar bone levels for teeth or sextants where BPE codes 3 or 4 are found assuming no false pockets.
=== Patent history === The U.S. Food and Drug Administration (FDA) approved tramadol in March 1995, and an extended-release (ER) formulation in September 2005. ER Tramadol was protected by US patents nos. 6,254,887 and 7,074,430. The FDA listed the patents' expiration as 10 May 2014. However, in August 2009, the US District Court for the District of Delaware ruled the patents invalid, a decision upheld the following year by the Court of Appeals for the Federal Circuit. Manufacture and distribution of generic equivalents of Ultram ER in the United States was therefore permitted before the expiration of the patents.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.